Skip to main content

Complicated Intra-abdominal Infection

10
Pipeline Programs
4
Companies
8
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
6
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 10 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
3 programs
1
1
1
MK0826; ertapenem sodiumPhase 41 trial
Imipenem+Cilastatin/RelebactamPhase 31 trial
Ceftolozane/TazobactamPhase 21 trial
Active Trials
NCT03217136Completed94Est. Mar 2020
NCT03293485Completed83Est. Sep 2018
NCT00157898Completed134Est. Sep 2004
MSD
MSDIreland - Ballydine
3 programs
1
1
1
MK0826; ertapenem sodiumPhase 4
Imipenem+Cilastatin/RelebactamPhase 3
Ceftolozane/TazobactamPhase 2
Pfizer
PfizerNEW YORK, NY
4 programs
4
ATM-AVIPhase 31 trial
CAZ-AVIPhase 31 trial
Ceftazidime-avibactamPhase 31 trial
PF-06947386Phase 31 trial
Active Trials
NCT03329092Completed422Est. Feb 2023
NCT01499290Completed493Est. Apr 2014
NCT01726023Completed486Est. Mar 2015
+1 more trials
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
CXA-201 and metronidazolePHASE_3Small Molecule1 trial
Active Trials
NCT01445678Completed494Est. Oct 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Sharp TherapeuticsMK0826; ertapenem sodium
PfizerPF-06947386
PfizerATM-AVI
Sharp TherapeuticsImipenem+Cilastatin/Relebactam
PfizerCeftazidime-avibactam
PfizerCAZ-AVI
Merck & Co.CXA-201 and metronidazole
Sharp TherapeuticsCeftolozane/Tazobactam

Clinical Trials (8)

Total enrollment: 2,266 patients across 8 trials

NCT00157898Sharp TherapeuticsMK0826; ertapenem sodium

A Study to Evaluate Ertapenem Versus It's Comparator in the Treatment of Complicated Intra-abdominal Infections in Adults (0826-050)(COMPLETED)

Start: Jan 2004Est. completion: Sep 2004134 patients
Phase 4Completed

Study to Assess Efficacy and Safety of PF-06947386 in Japanese Adult Patients With Complicated Intra-abdominal Infection

Start: Oct 2021Est. completion: Sep 202260 patients
Phase 3Completed

A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.

Start: Apr 2018Est. completion: Feb 2023422 patients
Phase 3Completed
NCT03293485Sharp TherapeuticsImipenem+Cilastatin/Relebactam

Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017)

Start: Oct 2017Est. completion: Sep 201883 patients
Phase 3Completed
NCT01726023PfizerCeftazidime-avibactam

Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections

Start: Jan 2013Est. completion: Mar 2015486 patients
Phase 3Completed

Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections

Start: Mar 2012Est. completion: Apr 2014493 patients
Phase 3Completed
NCT01445678Merck & Co.CXA-201 and metronidazole

Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections

Start: Dec 2011Est. completion: Oct 2013494 patients
Phase 3Completed
NCT03217136Sharp TherapeuticsCeftolozane/Tazobactam

MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)

Start: Apr 2018Est. completion: Mar 202094 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

6 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.